Myelodysplastic Syndromes (MDS)
Original Publication Date
Article Source
External Web Content
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and…
Firas El Chaer, MD
Institution
University of Virginia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at
Sabatolimab
Sabatolimab Sabatolimab: Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukem
Decitabine and Cedazuridine
INQOVI® for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups. It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:
Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia
Original Publication Date
Article Source
External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15…
Anand Karnad, MD
Institution
Mays Cancer Center at UT Health San Antonio MD Anderson
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center. He is
Science Simplified: What is a Natural History Study?
Original Publication Date
Article Source
External Web Content
Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works with researchers to make science accessible and empower rare disease community members with scientific knowledge. Dr…
Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
Original Publication Date
Article Source
External Web Content
Abstract Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and bone marrow cell morphology. The WHO guidelines suggest a visual screening of 200 to 500 cells which inevitably turns the assessor blind to rare cell populations…
Transplant for Older Patients with MDS
Topic(s)
Bone Marrow Transplant
Presenter(s)
Linda Burns, MD
Nandita Khera, MD, MPH
In this webinar Drs. Linda Burns and Nandita Khera will discuss the advances in transplantation for older patients with MDS. Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and…
Nandita Khera, MD, MPH
Institution
Mayo Clinic College of Medicine and Science
Physician Status
available for consultation
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
